大卫·A·里克斯
David A Ricks
领导U.S.大型Pharmaceuticals企业运营
专业领域
Healthcare management, life sciences
核心贡献
领导U.S.大型Pharmaceuticals企业运营
Leading large-scale Pharmaceuticals operations in U.S.
最新观点
-
礼来董事长兼CEO里克斯在2026年Q3业绩中表示,公司再次实现强劲季度并上调全年指引:营收同比增长39%至244亿美元,主要由Mounjaro与Zepbound的全球需求、Foundayo全球上市、美国肥胖症护理覆盖扩大以及肿瘤、免疫、神经科学新产品翻倍增长驱动;为支撑长期增长,公司持续投资制药与技术能力。
Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities.